EHS
EHS

STAT Plus: Pharmalittle: Vertex resumes talks with U.K. officials over pricing; Merck keeps its CEO around a little longer

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Our choice today is butter pecan. Remember that no prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch …

Vertex Pharmaceuticals (VRTX) and the U.K. government are expected to hold talks Thursday on resolving a high-profile and long-running impasse over pricing and coverage of an expensive cystic fibrosis drug, according to a patient group. The drug maker is expected to meet with the National Health Service in England and the National Institute for Health and Care Excellence, which determined the Orkambi treatment is not cost-effective, a move that prompted NHS officials to demand a lower price.

Continue to STAT Plus to read the full story…

EHS
Back to top button